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Abstract  
Background: Diuretics are the mainstay of treatment for congestion but concerns exist that 
they adversely affect prognosis. We explored whether the relationship between loop diuretic 
use and outcome is explained by the underlying severity of congestion amongst patients 
referred with suspected heart failure.   
Method and Results: Of 1190 patients, 712 had a left ventricular ejection fraction (LVEF) 
<50%, 267 had LVEF >50% with raised plasma NTproBNP (>400 ng/L) and 211 had LVEF 
>50% with NTproBNP <400ng/L; respectively, 72%, 68% and 37% of these groups were 
treated with loop diuretics including 28%, 29% and 10% in doses >80mg furosemide 
equivalent/day. 
 
Compared to patients with cardiac dysfunction (either LVEF <50% or NT-proBNP >400ng/L) 
but not taking a loop diuretic, those taking a loop diuretic were older and had more clinical 
evidence of congestion, renal dysfunction, anaemia and hyponatraemia. 
 
During a median follow-up of 934 (IQR: 513 – 1425) days, 450 patients were hospitalized for 
HF or died. Patients prescribed loop diuretics had a worse outcome. However, in multi-
variable models, clinical, echocardiographic (inferior vena cava diameter), and biochemical 
(NTproBNP) measures of congestion were strongly associated with an adverse outcome but 
neither the use, nor dose, of loop diuretics. 
 
Conclusions: Prescription of loop diuretics identifies patients with more advanced features of 
heart failure and congestion, which may account for their worse prognosis. Further research 
is needed to clarify the relationship between loop diuretic agents and outcome; imaging 
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and biochemical measures of congestion might be better guides to diuretic dose than 
symptoms or clinical signs. 
 
Key words: loop diuretic, heart failure, congestion, prognosis.  
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Introduction 
Amongst patients with heart failure, clinical (1, 2), echocardiographic (3-5), or biochemical 
(6-8) evidence of congestion is associated with an increased rate of hospitalization and higher 
mortality. Diuretics, especially high-ceiling diuretics acting on the Loop of Henle, are the 
mainstay of treatment for congestion in order to relieve symptoms and signs, but may activate 
the renin-angiotensin-aldosterone and sympathetic nervous systems which is thought to 
contribute to the progression and adverse outcome of heart failure (9, 10).   
 
However, there is a remarkable paucity of data on how diuretics should be best used to 
improve outcomes in heart failure. Conventional clinical practice is to use sufficient doses to 
relieve symptoms and signs of congestion. Once established, there is often no attempt to stop 
diuretic therapy to find out whether chronic daily dosing is required and there is often 
reluctance to prescribe higher doses to patients with more advanced heart failure (11). No 
randomised study has ever demonstrated whether loop diuretics alter mortality in patients 
with chronic heart failure although clearly they must be life-saving for patients with extreme 
congestion.  There is a strong association between the use of loop diuretic agents, especially 
in higher doses, and worse outcome (12, 13) but this may merely be a barometer of 
congestion (14). The observed relationship between diuretic dose, severity of congestion and 
outcome deserves further investigation.   
 
Accordingly, we compared the relation between diuretic dose, congestion and outcome in 
patients with chronic heart failure (either with reduced or normal left ventricular ejection 
fraction), using three different methods for assessing congestion: a clinical congestion scale; 
a biochemical measurement (natriuretic peptides); and imaging (inferior vena cava diameter). 
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Methods 
Study Population 
Out-patients attending a community heart failure clinic with suspected or confirmed heart 
failure (HF) between November 2008 and May 2013 were enrolled and followed for at least 
nine months.  HF was defined as symptoms or signs of HF, supported by objective evidence 
of cardiac dysfunction: either a left ventricular ejection fraction (LVEF) <50% at 
echocardiography or raised plasma concentration of amino-terminal pro-brain natriuretic 
peptide (NT-proBNP) (>400 ng/l) (15). Patients were grouped as: those without substantial 
evidence of cardiac dysfunction (NTproBNP <400 ng/l and LVEF >50%) and, for patients 
with HF, by the daily dose of loop diuretics taken (none, furosemide or equivalent < 40 
mg/day, >40 to 80 mg/day, > 80 mg/day). Those without objective evidence of cardiac 
dysfunction were further divided into patients with NT-proBNP <125 ng/l or NTproBNP 
between 125 ng/l and 400 ng/l (16).   
 
Patients provided a detailed clinical history and had blood tests (including haematology, 
biochemistry profile and NT-proBNP), ECGs and echocardiograms on the same day. 
Ischaemic heart disease was defined as a previous history of myocardial infarction or 
angiographic evidence of significant coronary artery disease (>70% on epicardial vessels). 
Diagnoses of hypertension and diabetes were based on prior medical history from medical 
records obtained from the general practitioner or from information collected at clinical visits. 
Patients in atrial fibrillation or atrial flutter were grouped as “AF”. 
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A congestion score was constructed, based on lung auscultation (normal, presence of basal, 
mid-zone or diffuse crepitations), JVP (not visible, raised 1-4 cm, raised to earlobe), 
peripheral oedema (none, ankles, below or above knees) and liver examination (not palpable, 
palpable) with one point attributed for each degree of severity and a total possible score of 
nine (17). 
 
Echocardiographic measurements 
Echocardiography was performed by experienced operators using a Vivid Five, Seven or Nine 
(GE Health Care, UK) system. Echocardiograms were reviewed by a single operator (PP) 
blinded to other patient details. LVEF was measured using Simpson’s biplane method. LA 
volume was indexed to body surface area (LAVI). Tricuspid annular plane systolic excursion 
(TAPSE) was used to assess RV systolic function. The trans-tricuspid systolic gradient was 
also measured when a suitable Doppler signal was available. With the patient supine, the 
maximum IVC diameter during the respiratory cycle was measured approximately three 
centimetres before merger with the right atrium.  
 
Congestion 
We used three indices as measures of congestion. 
1) Clinical congestion score: Patients with a score of 1 or 2 out of a possible score of nine 
were defined as mildly congested; those with a score of 3 or more were defined as severely 
congested (17). 
2) Echocardiographic congestion: we used the size of the inferior vena cava to define three 
groups. Patients with an IVC <16 mm were not considered to be congested, those with an IVC 
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17-20 mm were defined as mildly congested, those with an IVC >21 mm were considered 
severely congested. (18) 
3) Biochemical congestion: we used NTproBNP to define three groups, based on current and 
previous guidelines (Not congested: NTproBNP<125 ng/l; Possible congestion: 125-400 ng/l; 
congestion: NTproBNP > 400 ng/l; (15, 16)), or by classifying patients according to 
NTproBNP terciles (tercile 1, less congested; tercile 2: intermediate congestion; tercile 3: 
most congested).  
 
Data regarding hospitalizations and death were collected from the hospital’s electronic 
systems, supplemented by information from patients and their family doctors. The hospital is 
the only one in the region offering acute medical services. Outcome was censored at the point 
of last medical contact in either primary or secondary care. Vital status was confirmed from 
national records. The primary outcome was a composite of admission for worsening HF or 
death from all causes. Admission for HF was defined as an admission for worsening of 
relevant symptoms resulting in substantial intensification of treatment for HF.  
 
The study conforms to the principles outlined in the Declaration of Helsinki and was 
approved by relevant ethical bodies. All subjects gave their written informed consent for their 
data to be used at their first clinical visit. 
 
Statistical methods 
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Categorical data are presented as number and percentages; normally distributed 
continuous data as mean + standard deviation (SD); non-normally distributed variables 
as median and interquartile range (IQR).  
 
Student T-Test or Mann Whitney U test, and one-way analysis of variance and Kruskal-
Wallis tests were used to compare continuous variables between groups. Chi-squared 
tests were for categorical variables. Associations between variables and prognosis were 
assessed using Cox proportional hazards models.  Multivariable models were tested by 
progressively excluding the stronger variables associated with outcome in univariable 
analysis. Kaplan-Meier curves with the log-rank statistic were used to illustrate 
outcome. Analyses were performed using SPSS and Stata software, and a 2-sided P 
value < 0.05 was considered statistically significant. 
 
Results 
Patient characteristics 
Data for the overall population studied (n=1190) are shown in table 1; 979 patients (82 
%) had evidence of cardiac dysfunction and were considered to have heart failure, 
whilst 211 (18%) fulfilled neither imaging nor biomarker criteria for cardiac 
dysfunction and were considered not to have heart failure. 
 
The proportion of patients with or without heart failure taking loop diuretics was 71% 
and 37% respectively. Patients with heart failure taking loop diuretics had more 
evidence of congestion, especially those on higher doses. Patients taking higher doses 
Pellicori  Congestion & Loop Diuretics  28 Sept 2016 
 
9 
 
of loop diuretics were also older, more likely to have diabetes, had worse renal function 
and lower blood pressure, haemoglobin and serum sodium concentration. They also had 
lower left ventricular ejection fraction, larger left atrial volume, worse right ventricular 
systolic function, higher systolic pulmonary pressure and greater IVC diameter (Table 
1).  
 
For patients who did not fulfil criteria for heart failure whose plasma NTproBNP was 
125-400 ng/l, those who were taking loop diuretics had more symptoms and signs of 
congestion, worse renal function and higher heart rate compared to those who were not 
taking loop diuretics, but cardiac structure and function on echocardiography were 
similar (Table 1 supplementary). 
 
Amongst patients with NTproBNP <125 ng/l, those on loop diuretics were more likely 
to have IHD, had more symptoms and slightly higher natriuretic peptides than those 
who were not taking loop diuretics but no echocardiographic differences were observed 
between those on loop diuretics and those who were not. 
 
Loop diuretics and outcome 
The entire cohort was followed up for a median of 934 (IQR: 513 – 1425) days. There 
were 450 events (205 individuals were admitted to hospital with heart failure and 245 
died). There was a dose-response relation between daily dose of diuretic and outcome. 
Compared to patients with HF not taking loop diuretics, those treated with higher doses 
of loop diuretics (>80 mg furosemide per day or equivalent) had a markedly greater risk 
of an adverse event (HR: 3.50, 95% CI: 2.49-4.93) (Kaplan-Meier curve, Figure 1).  
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The relationship between loop diuretic use and outcome persisted in patients with heart 
failure with LVEF below and above 50% (Figures 2 and 3). 
 
Increasing clinical, echocardiographic or biochemical evidence of congestion were the 
major predictors of adverse outcome in patients with HF, rather than increasing doses 
of diuretics. For patients with heart failure who were not congested, the 1-year outcome 
was similar regardless of the amount of loop diuretic prescribed, whilst those patients 
with more evidence of congestion had a worse outcome for any given dose of diuretic. 
Patients with more severe congestion despite higher doses of loop diuretic agents had 
the worst outcome (table 2). 
 
In univariable Cox regression analysis (Table 3), clinical, biochemical and 
echocardiographic measures of congestion, as well as diuretic dose, predicted adverse 
outcome. 
 
In multivariable analysis, increases in all three indices of congestion (clinical score, 
IVC diameter and NT-proBNP) were independent predictors of a worse prognosis 
(Table 3). By contrast, diuretic dose was not independently associated with outcome 
and it is only when the six most powerful predictors are removed from the 
multivariable analysis that dose of diuretic enters the model (table 4).   
 
Discussion 
Prescription of diuretics remains, to a large extent, subjective, relatively evidence-free 
and therefore a focus for opinion-based medicine (11). There is a strong relationship 
between use and dose of loop diuretics and prognosis in patients with chronic heart 
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failure with either reduced or normal LVEF, but this analysis suggests that the 
relationship reflects the link between diuretic dose and severity of congestion, whether 
assessed clinically, by echocardiography, or using natriuretic peptides. After adjusting 
for the severity of congestion, the dose of diuretic taken did not predict outcome. 
However, diuretic dose can usually be readily obtained from the patient-record and is 
therefore a practical method of identifying those at greater risk of an adverse outcome in 
surveys, audits and trials.  
 
Current guidelines emphasize that diuretics are a treatment for the clinical symptoms 
and signs of congestion and that there is no evidence of a favourable effect on disease 
progression. There are theoretical concerns that, whilst relieving congestion, diuretics 
may cause neuro-endocrine (NE) activation and accelerate disease progression but there 
is no conclusive evidence that this is true. Moreover, introduction of NE antagonists 
may have reversed any adverse consequence of diuresis that once existed, especially the 
risk of hypokalaemia. Relief of congestion may reduce atrial and RV volumes and 
pulmonary artery pressure (19). There is evidence that the severity of RV rather than 
LV dysfunction is more tightly linked to prognosis (3, 5) and increased atrial pressure 
and volume may provoke AF (17). Therefore, achieving euvolaemia through adequate 
diuresis, protected by agents that block NE activation and hypokalaemia, might have 
favourable effects on disease progression. Indeed, potassium sparing diuretics 
appear associated with better outcomes in observational studies of diuretics in 
heart failure (12), perhaps because they prevent hypokalaemia and reduce the 
propensity of arrhythmias or perhaps because they replete intracellular potassium 
thereby improving the metabolic function of cells, including skeletal muscle and 
cardiac myocytes (20). 
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The effects of diuretics on renal function are complex (21). In patients with severe 
oedema, diuretics may reduce renal parenchymal oedema and renal venous pressure 
without reducing renal arterial perfusion pressure, leading to improved renal function. 
In patients with less grossly elevated venous pressure, the fall in renal arterial perfusion 
pressure and complex changes in adenosine, intra-renal haemodynamics and tubulo-
glomerular feedback conspire to cause a decline in glomerular filtration rate (21). 
Moreover, washout of the medullary concentration gradient and other ‘braking’ effects 
may lead to varying degrees of tolerance to diuretic effects. High-dose loop diuretics 
may also cause hypochloraemia, which may contribute to diuretic resistance, 
neuro-endocrine activation and an adverse prognosis (22, 23). 
Although a meta-analysis including three small randomized trials enrolling 202 patients 
in total suggested that mortality might be lower for those patients treated with diuretics 
compared to placebo (24), no randomised prospective study has evaluated the impact of 
loop diuretics on mortality in patients with chronic heart failure. Given the need to use 
diuretics to control symptoms of congestion, the low event rates in patients with cardiac 
dysfunction who do not have congestion and the possibility that diuretics are only safe 
and effective in patients who have congestion, it is difficult to design definitive outcome 
studies to address the topic. Clearly, for patients with severe congestion about to die of 
fluid overload, diuretics must be life-saving.  
 
Retrospective analyses of several RCTs have raised concerns about a possible detrimental 
effect of long-term loop diuretic therapy.  In the Prospective Randomized Amlodipine 
Survival Evaluation (PRAISE) trial (13), the use of furosemide >80mg/day (or equivalent 
dose of other diuretics) or the use of metolazone combined with a loop diuretic, were 
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independent predictors or mortality. In a sub-analysis of the Studies of Left Ventricular 
Dysfunction (SOLVD) (12), amongst >6000 patients with moderate or severe left ventricular 
dysfunction, the risk of hospitalization or death due to worsening HF in patients taking non-
potassium sparing diuretics alone was greater (risk ratio [RR] 1.31, 95% CI 1.09 to 1.57; 
p=0.0004) when compared to those not taking any diuretic. Recently, Damman and coauthors 
examined the relationship between loop diuretic use and dose with a composite outcome of 
cardiovascular death or hospitalization for HF by propensity score matching different cohorts 
of patients with systolic dysfunction enrolled in the Controlled Rosuvastatin Multinational 
Trial in Heart Failure (CORONA) trial. They also suggested that the use of diuretics was 
associated with an adverse outcome, particularly a higher risk of admissions for heart failure 
(25). Eshaghian and colleagues (14) also found that use of more intense diuretic treatment 
was associated with a worse outcome. They noted that those who were prescribed higher 
doses of diuretics (>160 mg of furosemide) had more severe symptoms, lower LV ejection 
fraction and cardiac index, and higher pulmonary capillary wedge pressure than those not 
taking, or taking lower doses of loop diuretics. Similar to our results, those taking >160 mg 
furosemide had an almost 4-fold increased risk of death compared to those taking furosemide 
0-40 mg/day.  
 
However, assessing the effect of diuretics on outcome is inevitably confounded by indication; 
the perceived need to prescribe them to control symptoms and signs of congestion. Propensity 
matched analyses, unless done before initiation of diuretics, are systematically biased and 
irrevocably confounded, since diuretics influence many key prognostic variables such as 
blood pressure, electrolytes and renal function resulting in systematic error that is likely to 
match patients on diuretics to patients who have a very different intrinsic prognosis. Multi-
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variable analysis, as presented in this paper, is less likely to be confounded than other 
statistical approaches to this issue.  
 
The relationship between diuretic dose and severity of congestion deserves further 
consideration. In one sense, being congested whilst taking a loop diuretic can be 
considered treatment failure, since diuretics are being used in an attempt to control 
congestion but have failed to do so adequately. This may reflect over-cautious use. 
Alternatively, continuing congestion despite administration of diuretics could reflect a 
deleterious drug effect accelerating disease progression. More aggressive treatment with 
higher doses of loop diuretics might have reduced congestion but may aggravate renal 
dysfunction with uncertain effects on symptoms and prognosis. There is perhaps more 
evidence addressing the question than is immediately apparent. A series of RCTs has 
investigated whether treatment guided by natriuretic peptides, a biomarker of 
congestion, improves outcomes. The results of these studies have been inconclusive, but 
often because the treatment strategy failed to reduce natriuretic peptides (26, 27). In 
some successful studies, the key intervention that reduced NP was higher doses of 
diuretics (28, 29). Implanted haemodynamic monitoring devices also suggest that 
appropriate intensification of diuretic doses improves well-being and outcome (30). 
Thus, one interpretation of these trials is that treating persisting congestion with higher 
doses of diuretics improves outcome.   
 
Despite the general belief that achieving the lowest tolerated dose, or even withdrawal, 
of loop diuretics, might be beneficial for patients with heart failure, our study suggests 
that it might not be appropriate due the risk of recurrent congestion, since congestion 
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rather than diuretic dose was more strongly linked to outcome. Many patients diagnosed 
with heart failure, some probably erroneously, can tolerate prolonged withdrawal of 
diuretic therapy but it is not clear whether withdrawal improves symptoms or outcome 
and it does put patients at increased risk of decompensation (31, 32).  On the other hand, 
treating patients who do not have overt clinical evidence of congestion with loop 
diuretics cannot improve symptoms but may cause NE activation (33).  
Loop diuretics are commonly prescribed for breathlessness or oedema in the absence of 
evidence of substantial cardiac dysfunction. Such patients in our study had an adverse 
outcome compared to those not taking loop diuretics, although this might reflect the 
higher prevalence of comorbidities, such as ischaemic heart disease. Alternatively, 
diuretics may have reduced plasma concentrations of NT-proBNP and left atrial 
volume, thereby masking evidence of cardiac dysfunction. Although diuretics might be 
discontinued in many of these patients, further trials to demonstrate the safety and 
tolerability of diuretic withdrawal are needed.   
 
Limitations 
There is no universally accepted definition of heart failure. Of patients with LVEF 
<50%, 36 (5%) had an NT-proBNP <125ng/L and some might consider these patients 
did not have heart failure. Many would not accept elevation of NT-proBNP alone as 
diagnostic of heart failure. Of patients with an NT-proBNP >400ng/L and LVEF >50%, 
166 (60%) were in AF, 22 (8%) had eGFR <30ml/minute, only 67 (25%) had a normal 
LA volume (LAVI<34 mL/m2 (18)) and 181 (68%) were taking loop diuretics. Thus, 
very few patients with NT-proBNP >400ng/L had no other evidence of major cardiac 
dysfunction. On the other hand, loop diuretics may have concealed underlying cardiac 
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dysfunction, normalizing NT-proBNP and atrial volumes. Withdrawal of diuretics is 
likely to have revealed evidence of cardiac dysfunction in some patients. 
 
Conclusions 
The presence of congestion assessed either clinically, by echocardiography or by plasma 
concentrations of natriuretic peptides, identifies patients with chronic heart failure at high risk 
of an adverse outcome whether or not they are taking loop diuretics. Diuretics are more likely 
to be a marker of, rather than a cause of, a worse prognosis in patients with heart failure 
receiving contemporary therapy with NE antagonists that prevent hypokalaemia. However, 
further research is needed to clarify the relationship between loop diuretic agents and 
outcome; imaging and biochemical measures of congestion might be better guides to 
diuretic dose than symptoms or clinical signs. 
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Legend to figures 
Figure 1. Kaplan Meier curve for the primary outcome of death from all causes and 
heart failure hospitalizations in the overall population. Compared to patients with 
heart failure not taking loop diuretics, those treated with higher doses of loop diuretics 
(>80 mg furosemide per day) had a markedly greater risk of an adverse event (HR: 
3.50, 95% CI: 2.49-4.93, p<0.001). 
 
Figure 2. Kaplan Meier curve for the primary outcome of death from all causes and 
heart failure hospitalizations in patients with HF and reduced left ventricular ejection 
fraction (LVEF<50%). Compared to patients not taking loop diuretics, those treated 
with any dose of loop diuretic had a 2-fold increased risk of an adverse event (HR: 
2.18, 95% CI: 1.62-2.95, p<0.001). The risk increased with increasing dose of loop 
diuretic taken (Dose > 40 mg/day vs no diuretic: HR: 2.95, 95% CI: 2.13-4.10, 
p<0.001; Dose=10- 40 mg/day vs no diuretic: HR: 1.76, 95% CI: 1.27-2.43, p=0.001). 
 
Figure 3. Kaplan Meier curve for the primary outcome of death from all causes and 
heart failure hospitalizations in patients with raised NTproBNP (>400 ng/l) and 
normal LVEF (>50%). Compared to patients not taking loop diuretics, those treated 
with any dose of loop diuretic had a 3-fold increased risk of an adverse event (HR: 
3.04, 95% CI: 1.83-5.04, p<0.001). 
Variable Missing  No HF 
NTproBNP < 125  
ng/l 
No HF  
125<NTproBNP<400  
ng/l 
HF  
 no loop 
diuretics 
HF  
10 to 40 mg 
Furosemide 
HF  
>40 to 80 mg 
Furosemide 
HF  
> 80 
Furosemide 
 
P between 
HF groups 
Patients – no. NA 102 109 283 411 177 108 NA 
Demographic 
Age - years 0 65 (51-71) 72 (66-79) 73 (64-80) 75 (69-81) 75 (67-81) 77 (67-82) 0.013 
Sex (male) – no. (%) 0 62 (61) 61 (56) 209 (74) 279 (68) 126 (76) 82 (76) 0.227 
IHD – no. (%) 0 23 (22) 40 (36) 176 (62) 257 (63) 109 (62) 81 (75) 0.078 
DM– no. (%) 0 39 (38) 44 (40) 67 (24) 115 (28) 69 (39) 50 (46) <0.001 
HTN– no. (%) 0 65 (64) 84 (77) 170 (60) 216 (53) 85 (48) 50 (46) 0.024 
COPD– no. (%) 0 12 (12) 17 (16) 21 (7) 47 (11) 24 (14) 15 (14) 0.116 
NYHA class I– no. (%) 
NYHA class II– no. (%) 
NYHA class III– no. (%) 
 
0 
61 (60) 46 (42) 87 (31) 63 (15) 14 (8) 3 (3)  
<0.001 30 (29) 34 (31) 150 (53) 208 (51) 95 (54) 37 (34) 
11( 11) 29 (27) 46 (16) 140 (34) 68 (38) 68 (63) 
Congested– no. (%) 0 7 (7) 9 (8) 17 (6) 60 (15) 34 (19) 37 (34) <0.001 
AF– no. (%) 0 1 (1) 8 (7) 81 (29) 150 (37) 74 (41) 59 (55) <0.001 
BMI- kg/m2 0 30.6 (5.6) 32.1 (6.9) 28.7 (5.3) 28.3 (5.8) 29.5 (6.2) 29.6 (6.0) 0.198 
SBP – mmHg 0 136 (20) 140 (22) 135 (24) 129 (24) 121 (23) 124 (25) <0.001 
HR- bpm 0 73 (13) 71 (14) 70 (14) 71 (15) 73 (13) 72 (14) 0.159 
Blood results  
Haemoglobin - g/dl 1 14.1 (1.4) 13.5 (1.5) 13.7 (1.6) 13.1 (1.7) 12.9 (1.7) 12.6 (1.9) <0.001 
Creatinine - umol/l 0 79 (65-93) 90 (74-110) 90 (79-109) 105 (87-141) 113 (92-143) 131 (100-180) <0.001 
eGFR– ml/min/1.73m2 0 86 (71-108) 72 (56-90) 72 (58-85) 59 (42-75) 55 (41-71) 46 (31-64) <0.001 
Na – mmol/l 0 139 (2) 138 (3) 138 (3) 138 (3) 138 (3) 137 (4) 0.005 
K – mmol/l 5 4.2 (0.4) 4.4 (0.4) 4.4 (0.4) 4.4 (0.5) 4.4 (0.5) 4.3 (0.5) 0.241 
NTproBNP– ng/l 2 51 (29-85) 236 (161-291) 794 (381-1596) 1310 (628-2939) 1717 (735-3120) 1966 (1120-4572) <0.001 
Urea – mmol/l 0 4.8 (3.9 – 5.8) 6.4 (4.7-7.8) 5.8(4.6-7.2) 7.8 (5.9-10.30) 8.8 (6.4-11.8) 11.7 (8.3-16.1) <0.001 
Albumin – g/l 1 40 (3) 39 (3) 39 (3) 38 (3) 38 (3) 37 (4) <0.001 
Bilirubin– umol/l 0 12 (10-15) 13 (11-15) 14 (12-18) 14 (12-18) 15 (12-19) 16 (12-22) 0.028 
Treatment 
Beta-blockers– no. (%) 0 32 (31) 58 (53) 222 (78) 332 (81) 151 (85) 82 (76) 0.187 
 Table 1: Characteristics of patients by diagnosis and by amount of loop diuretic taken (only for those with HF). List of abbreviation used: IHD - 
Ischemic Heart Disease; DM – Diabetes Mellitus; COPD - Chronic Obstructive Pulmonary Disease; HTN: hypertension; SBP - Systolic Blood 
Pressure; HR: heart rate; BMI - Body Mass Index; eGFR - estimated Glomerular Filtration Rate; AF: atrial fibrillation; NTproBNP –N-terminal 
B-type natriuretic peptide; LVEDV - Left Ventricle End Diastolic Volume; LVEF – Left Ventricular Ejection Fraction; LAVI - Left Atrial 
Volume Index; TAPSE - Tricuspid Annular Plane Systolic Excursion; TR gradient- Trans-Tricuspid systolic gradient; IVC: inferior vena cava, 
HF: heart failure; MRA: Mineralocorticoid receptor antagonists; ACE-I: angiotensin-converting-enzyme inhibitor; ARB: Angiotensin II receptor 
blockers, NA: not applicable. *NTproBNP<125 vs 125-400. 
ACE-I or ARB– no. (%) 0 58 (57) 81 (74) 230 (81) 359 (87) 163 (92) 92 (85) 0.009 
MRA– no. (%) 0 14 (14) 17 (16) 59 (21) 148 (36) 98 (55) 61 (56) <0.001 
Loop– no. (%) 0 28 (27) 50 (46) NA NA NA NA 0.006* 
Loop > 40 mg/day– no. (%) 0 3 (3) 17 (16) NA NA NA NA <0.001* 
Bendroflumethiazide– no. (%) 0 NA NA 34 (13) 2 (1) 1 (1) 2 (2) <0.001 
Metolazone– no. (%) 0 NA NA 0 0 3 (2) 3 (3) 0.001 
Echocardiography 
LVEDV – ml 0 100 (78-114) 90 (68-114) 137 (100-178) 158 (111-202) 153 (110-198) 146 (109-197) 0.001 
LVEF - % 0 59 (55-53) 59 (55-64) 45 (36-54) 40 (32-51) 40 (31-50) 42 (30-55) 0.003 
LVEF<40% 0 NA NA 111 (39) 206 (50) 89 (50) 50 (46) 0.027 
LAVI - ml/m2 0 23 (20-27) 28 (21-35) 37 (29-51) 43 (32-56) 43 (33-58) 51 (37-65) <0.001 
TAPSE – mm 2 22 (19-25) 21 (17-24) 20 (16-22) 18 (15-21) 17 (14-20) 16 (13-20) <0.001 
TR gradient – mmHg 39 17 (16-21) 20 (16-25) 25 (20-31) 25 (20-33) 26 (20-37) 31 (22-40) <0.001 
IVC – mm 38 15 (14-17) 15 (14-17) 18 (16-21) 19 (16-23) 19 (17-23) 22 (18-26) <0.001 
E/e’  735 7 (6-9) 9 (7-11) 10 (9-14) 12 (10-17) 13 (9-17) 15 (10-19) 0.002 
Events 
Deaths– no. (%) NA 6 (6) 21 (19) 45 (16) 135 (33) 66 (37) 50 (46) NA 
HF Hospitalizations– no. (%) NA 5 (5) 11 (10) 34 (12) 81 (20) 50 (28) 24 (22) NA 
 1-year event free 
survival 
  
No loop diuretic 
 
Lower dose loop 
diuretic 
(<40 mg) 
 
Higher dose loop 
diuretic 
(>40 mg) 
 
 
p@ 
Clinical congestion 
Not congested (0) 92% 87% 85% 0.123 
Mild congestion (1-2) 90% 84% 76% 0.062 
Great congestion (>3) 73% 71% 54% 0.109 
P#  0.054 0.009 <0.001  
Biochemical* 
Not congested (NTproBNP<125 ng/l) 100% 100% 100% 1 
Mild congestion (NTproBNP=125-400 ng/l) 98% 93% 100% 0.267 
Great congestion (NTproBNP > 400 ng/l) 88% 82% 72% <0.001 
P#  0.025 0.066 0.009  
Biochemical** 
NTproBNP tercile 1 98% 95% 90% 0.048 
NTproBNP tercile 2 91% 87% 72% 0.001 
NTproBNP tercile 3 83% 70% 61% 0.005 
P#  0.002 <0.001 <0.001  
Echocardiographic 
No congestion (IVC < 16 mm) 95% 92 % 88% 0.342 
Mild congestion (IVC 17-20 mm) 92 % 92 % 83% 0.101 
Great congestion (IVC > 21 mm) *** 82 % 71% 61% 0.006 
P#  0.030 <0.001 <0.001  
 
Table 2: 1-year event free survival. 965 patients with HF were followed-up for at least 365 days unless censored due to an event. During the first 365 days 
163 events were recorded. NTproBNP was not available for two patients, for 34 patients IVC diameter was not available. P for significance amongst groups 
of patients treated with increasing dose of loop diuretics (@) or by increasing clinical, biochemical or echocardiographic congestion (#, highlighted in bold) 
are reported. 
*Median NTproBNP per group:  No Loop diuretic 1107 (692-1911) ng/l; Lower dose Loop diuretic: 1526 (857-3325) ng/l; Higher dose Loop diuretic: 1962 
(1133-3924) ng/l; p<0.001. **Median NTproBNP per group: Tercile 1: No Loop diuretic: 224 (143-378)ng/l; Lower dose Loop diuretic: 445 (237-632)ng/l; 
Higher dose Loop diuretic: 586 (381-846)ng/l, p<0.001; Tercile 2: No Loop diuretic: 790 (613-1021)ng/l; Lower dose Loop diuretic: 1289 (1088-1623)ng/l; 
Higher dose Loop diuretic: 1869 (1503-2129)ng/l, p<0.001; Tercile 3: No Loop diuretic 2012 (1573-3266)ng/l; Lower dose Loop diuretic: 4020 (2926-
6342)ng/l; Higher dose Loop diuretic: 4837 (3556-8487)ng/l, p<0.001. 
***Median NTproBNP per group:  No Loop 1736 (997-3267) ng/l; Lower dose Loop diuretic: 2877 (1471-4890) ng/l; Higher dose Loop diuretic: 2917 (1663-
5506) ng/l; p<0.001; Median IVC per group:  No Loop diuretic 23 (22-24) mm; Lower dose Loop diuretic: 24 (22-27) mm; Higher dose Loop diuretic: 24 (22-
27) mm; p=0.001. 
 
  
Variables 
 
Univariable analysis 
 
Multivariable analysis 
 HR (95% CI) χ2 p-value HR (95% CI) χ2 p-value 
Age - years 1.04 (1.03-1.05) 73.78 <0.001 1.03 (1.01-1.04) 14.88 <0.001 
Sex (men) 0.96 (0.77-1.18) 0.16 0.69    
IHD(yes vs no) 1.10 (0.90-1.35) 0.95 0.33    
DM (yes vs no) 1.07 (0.87-1.31) 0.38 0.54    
HTN(yes vs no) 0.91 (0.75-1.10) 0.95 0.33    
COPD(yes vs no) 1.11 (0.83-1.49) 0.48 0.48    
NYHA class III vs I/II 2.22 (1.83-2.70) 64.94 <0.001 1.52 (1.21-1.92) 12.99 <0.001 
Congested (yes vs no) 2.34 (1.86-2.96) 51.55 <0.001 1.38 (1.01-1.86) 4.20 0.04 
AF (yes vs no) 1.32 (1.08-1.60) 7.51 0.006    
BMI - kg/m2 0.96 (0.94-0.98) 19.31 <0.001    
SBP- mmHg 0.99 (0.99-1.00) 4.19 0.041    
HR- bpm 1.01 (1.00-1.01) 3.82 0.051    
Haemoglobin - g/dl 0.81 (0.76-0.85) 57.95 <0.001    
Creatinine - umol/l 1.01 (1.00-1.01) 69.97 <0.001    
eGFR-  ml/min/1.73m2 0.98 (0.97-0.99) 63.72 <0.001    
Na– mmol/l 0.92 (0.90-0.95) 26.36 <0.001 0.95 (0.92-0.98) 9.76 0.002 
K– mmol/l 1.27 (1.03-1.58) 4.99 0.026    
LogNTproBNP 3.87 (3.18-4.72) 181.65 <0.001 1.58 (1.15-2.17) 7.93 0.005 
Urea- mmol/l 1.09 (1.08-1.11) 127.50 <0.001 1.06 (1.03-1.09) 12.71 <0.001 
Albumin – g/l 0.91 (0.88-0.93) 44.88 <0.001    
Bilirubin– umol/l 1.03 (1.01-1.04) 13.32 <0.001    
LD > 80 vs < 80 mg/day 1.96 (1.50-2.55) 24.14 <0.001    
 
 
 
 
 
 
 
 
 
 
Table 3:  Univariable and multivariable Cox regression models for the composite endpoint of death or HF hospitalization in patients with HF. 
The independent predictors of adverse outcome are highlighted in bold. List of abbreviation used: IHD - Ischemic Heart Disease; DM – Diabetes 
Mellitus; COPD - Chronic Obstructive Pulmonary Disease; HTN: hypertension; SBP - Systolic Blood Pressure; HR: heart rate; BMI - Body 
Mass Index; eGFR - estimated Glomerular Filtration Rate; AF: atrial fibrillation; NTproBNP –N-terminal B-type natriuretic peptide; LD – loop 
diuretic; LVEDV - Left Ventricle End Diastolic Volume; LVEF – Left Ventricular Ejection Fraction; LAVI - Left Atrial Volume Index; TAPSE 
- Tricuspid Annular Plane Systolic Excursion; TR gradient- Trans-Tricuspid systolic gradient; IVC: inferior vena cava. 
 
 
LVEDV- ml 1.01 (1.00-1.01) 10.22 0.001    
LVEF- % 0.99 (0.98-1.00) 9.19 0.002    
LAVI - ml/m2 1.02 (1.01-1.02) 76.33 <0.001    
TAPSE – mm 0.93 (0.91-0.95) 46.48 <0.001    
TR gradient – mmHg 1.03 (1.03-1.04) 90.36 <0.001    
IVC – mm 1.11 (1.10-1.11) 138.92 <0.001 1.06 (1.03-1.09) 15.15 <0.001 
Table 4 – Multivariable Cox regression models. Different multivariable Cox regression models for the composite endpoint of death or HF 
hospitalization in patients with HF were tested. All the variables on the left column have been included, and then we consecutively excluded the 
strongest variable(s) in the univariable analysis (those excluded are reported above each column from each model). X identifies variables that 
entered the multivariable models tested with a P<0.05. List of abbreviation used: SBP - Systolic Blood Pressure; BMI - Body Mass Index; eGFR 
Variable LogNTproBNP 
removed 
LogNTproBNP 
& IVC  
removed 
LogNTproBNP 
& IVC & Urea  
removed 
LogNTproBNP 
& IVC & Urea 
& TR grad  
removed 
LogNTproBNP 
& IVC & Urea 
& TR grad & 
LAVI  
removed 
LogNTproBNP 
& IVC & Urea 
& TR grad & 
LAVI & 
Creatinine  
removed 
LogNTproBNP 
& IVC & Urea 
& TR grad & 
LAVI & 
Creatinine & 
Congested  
removed 
Age - years X X X X X X X 
NYHA class III vs I/II X X X X X X X 
Congested – yes vs not X       
AF– yes vs not        
BMI- kg/m2        
SBP - mmHg        
HR- bpm         
Haemoglobin - g/dl      X X 
Creatinine- umol/l   X     
Na– mmol/l X X X X X X X 
K– mmol/l        
Urea- mmol/l X X      
Albumin – g/l    X X X X 
Bilirubin– umol/l     X X X 
LD > 80 vs < 80 mg/day      X X 
LVEDV- ml     X X X 
LVEF- %        
LAVI- ml/m2  X X X    
TAPSE– mm    X X X X 
TR gradient– mmHg X X X     
IVC– mm X       
- estimated Glomerular Filtration Rate; HR: heart rate; AF: atrial fibrillation; NTproBNP –N-terminal B-type natriuretic peptide; LD: loop 
diuretic; LVEDV - Left Ventricle End Diastolic Volume; LVEF – Left Ventricular Ejection Fraction; LAVI - Left Atrial Volume Index; TAPSE 
- Tricuspid Annular Plane Systolic Excursion; TR gradient- Trans-Tricuspid systolic gradient; IVC: inferior vena cava. 
 
